Zuberitamab

泽贝妥单抗

Report date: 2026/03/24 20:00:35

Base Information

Drug NameZuberitamab
Drug Alias NameRHCACD20MARecombinant human-mouse chimeric anti-CD20 monoclonal antibody injection - Zhejiang Hisun Pharmaceutical安瑞昔HS-006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicNephrosis +[9] 
Global Approved IndicationsLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Large B-Cell, Diffuse
Original Approved Country/TerritoryMainland China
Original Approved Date2023/05/12
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBioRay Pharmaceutical Co LtdInstitute Of Hematology & Blood Diseases HospitalZhejiang BioRay Biopharmaceuticals Co Ltd +[4] 
Inactive CompaniesZhejiang Hisun Pharmaceutical Co Ltd
Active IndicationsNephrosisGlomerulonephritis, MembranousArthritis, Rheumatoid +[6] 
Inactive IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicLymphoma, Non-Hodgkin

Other Information

ATC CodeL01XC02
Related LinksN/A